Vinay Prasad's Controversial Exit from the FDA
Vinay Prasad, appointed as FDA's top vaccine official, faced criticism and backlash during his short tenure. Controversies surrounded gene therapy safety and regulatory decisions affecting futures of several biotech firms. His exit raises questions about the FDA's current direction amid major leadership changes under U.S. Health Secretary Robert F. Kennedy Jr.
Vinay Prasad, the U.S. FDA's Chief of the Center for Biologics Evaluation and Research, has resigned after just three months following controversial decisions and growing criticism of his leadership, particularly regarding the safety of a gene therapy for Duchenne muscular dystrophy.
Earlier this week, criticism peaked with accusations by far-right activist Laura Loomer and unfavorable opinion pieces, leading to his decision to step down to avoid being a distraction. His tenure saw regulatory shakeups and impacted the stock values of firms like Replimmune, Sarepta, and Capricor Therapeutics.
Prasad's departure signifies ongoing leadership instability within the FDA, raising questions on future policies and regulatory decisions as biotech firms and analysts express concerns over the agency's direction under U.S. Health Secretary Robert F. Kennedy Jr.
(With inputs from agencies.)
Google News